Table 1 Patients' characteristics of the three treatment groups analyzed in this follow-up study
Treatment group | Total | p-value | ||||
|---|---|---|---|---|---|---|
Antibody18 ch14.18 | Oral NB90 maintenance18 chemotherapy | No consolidation | ||||
No. of patients | 166 | 99 | 69 | 334 | ||
Age at diagnosis | median (years) | 3.2 | 2.9 | 2.9 | 3.2 | .262 |
range (years) | 1.0-20.6 | 1.0-15.0 | 1.0-11.2 | 1.0-20.6 | ||
Sex | male | 95 | 54 | 43 | 192 | .602 |
female | 71 | 45 | 26 | 142 | ||
Protocol | NB90 | 25 | 99 | 53 | 177 | <.001 |
NB97 | 141 | 0 | 16 | 157 | ||
ASCT | no | 63 | 99 | 27 | 189 | <.001 |
yes | 103 | 0 | 42 | 145 | ||
MYCN status | Normal | 124 | 56 | 34 | 214 | .358 |
Amplified | 38 | 15 | 16 | 69 | ||
Not known | 4 | 28 | 19 | 51 | ||
Disease status after initial treatment | CR/VGPR | 134 | 81 | 52 | 267 | .567 |
PR | 27 | 17 | 16 | 60 | ||
MR/SD | 5 | 1 | 1 | 7 | ||